{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:44:54Z","timestamp":1783421094519,"version":"3.54.6"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>The bioequivalence of denosumab biosimilar has yet to be studied in a 53-week, multicenter, large-scale, and head-to-head trial. A clinically effective biosimilar may help increase access to denosumab in patients with solid tumor\u2013related bone metastases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To establish the biosimilarity of MW032 to denosumab in patients with solid tumor\u2013related bone metastases based on a large-scale head-to-head study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>In this 53-week, randomized, double-blind, phase 3 equivalence trial, patients with solid tumors with bone metastasis were recruited from 46 clinical sites in China. Overall, 856 patients were screened and 708 eligible patients were randomly allocated to receive either MW032 or denosumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Patients were randomly assigned (1:1) to receive MW032 or reference denosumab subcutaneously every 4 weeks until week 49.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary end point was percentage change from baseline to week 13 of natural logarithmic transformed urinary N-telopeptide\/creatinine ratio (uNTx\/uCr).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 701 evaluable patients (350 in the MW032 group and 351 in the denosumab group), the mean (range) age was 56.1 (22.0-86.0) years and 460 patients were women (65.6%). The mean change of uNTx\/uCr from baseline to week 13 was \u221272.0% (95% CI, \u221273.5% to \u221270.4%) in the MW032 group and \u221272.7% (95% CI, \u221274.2% to \u221271.2%) in the denosumab group. These percent changes corresponded to mean logarithmic ratios of \u22121.27 and \u22121.30, or a difference of 0.02. The 90% CI for the difference (\u22120.04 to 0.09) was within the equivalence margin (\u22120.13 to 0.13); the mean changes of uNTx\/uCr and bone-specific alkaline phosphatase (s-BALP) at each time point were also similar during 53 weeks. The differences of uNTx\/uCr change were 0.015 (95% CI, \u22120.06 to 0.09), \u22120.02 (95% CI, \u22120.09 to 0.06), \u22120.05 (95% CI, \u22120.13 to 0.03) and 0.001 (95% CI, \u22120.10 to 0.10) at weeks 5, 25, 37, and 53, respectively. The differences of s-BALP change were \u22120.006 (95% CI, 0.06 to 0.05), 0.00 (95% CI, \u22120.07 to 0.07), \u22120.085 (95% CI, \u22120.18 to 0.01), \u22120.09 (95% CI, \u22120.20 to 0.02), and \u22120.13 (95% CI, \u22120.27 to 0.004) at weeks 5, 13, 25, 37 and 53, respectively. No significant differences were observed in the incidence of skeletal-related events (\u22121.4%; 95% CI, \u22125.8% to 3.0%) or time to first on-study skeletal-related events (unadjusted HR, 0.86; <jats:italic>P<\/jats:italic>\u2009=\u2009.53; multiplicity adjusted HR, 0.87; <jats:italic>P<\/jats:italic>\u2009=\u2009.55) in the 2 groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>MW032 and denosumab were biosimilar in efficacy, population pharmacokinetics, and safety profile. Availability of denosumab biosimilars may broaden the access to denosumab and reduce the drug burden for patients with advanced tumors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9971153\/\">NCT04812509<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2023.6520","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T16:05:01Z","timestamp":1707408301000},"page":"448","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor\u2013Related Bone Metastases"],"prefix":"10.1001","volume":"10","author":[{"given":"Shaohua","family":"Zhang","sequence":"first","affiliation":[{"name":"Senior Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Jiangsu, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Xiong","sequence":"additional","affiliation":[{"name":"Huizhou Central People\u2019s Hospital, Huizhou, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfen","family":"Wang","sequence":"additional","affiliation":[{"name":"Linyi Cancer Hospital, Linyi, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Liu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of USTC\/Anhui Provincial Cancer Hospital, Hefei, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junguo","family":"Lu","sequence":"additional","affiliation":[{"name":"Nantong Tumor Hospital, Nantong, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Harbin Medical University Cancer Hospital, Harbin, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longzhen","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Xuzhou Medical University, Xuzhou, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincai","family":"Zhong","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangxi Medical University, Nanning, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyun","family":"Nie","sequence":"additional","affiliation":[{"name":"Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijian","family":"Lei","sequence":"additional","affiliation":[{"name":"The Second People\u2019s Hospital of Yibin, Yibin, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[{"name":"Nanchang People\u2019s Hospital, Nanchang, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Yang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, The First Clinical Medicine School of Guangdong Pharmaceutical University, Guangzhou, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herui","family":"Yao","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijing","family":"Wu","sequence":"additional","affiliation":[{"name":"Hubei Cancer Hospital, Wuhan, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Yu","sequence":"additional","affiliation":[{"name":"Hubei Cancer Hospital, Wuhan, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuening","family":"Ji","sequence":"additional","affiliation":[{"name":"Zhongshan Clinical Collage of Dalian University, Dalian, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Xinjiang Medical University, Urumchi, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanchang University, Nanchang, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Xie","sequence":"additional","affiliation":[{"name":"Guangxi Medical University Cancer Hospital, Nanning, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"The First Bethune Hospital of Jilin University, Changchun, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weirong","family":"Yao","sequence":"additional","affiliation":[{"name":"The Jiangxi Provincial People\u2019s Hospital, Nanchang, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diansheng","family":"Zhong","sequence":"additional","affiliation":[{"name":"Tianjin Medical University General Hospital, Tianjin, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Sun","sequence":"additional","affiliation":[{"name":"Jiamusi Cancer Hospital, Jiamusi, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[{"name":"Liaoning Cancer Hospital & Institute, Shenyang, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengqing","family":"Guo","sequence":"additional","affiliation":[{"name":"Fujian Cancer Hospital, Fuzhou, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[{"name":"Anhui Chest Hospital, Hefei, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhen","family":"Guo","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Yu","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Qingdao University, Qingdao, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dairong","family":"Li","sequence":"additional","affiliation":[{"name":"Chongqing University Cancer Hospital, Chongqing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Jin","sequence":"additional","affiliation":[{"name":"Puren Hospital of Wuhan, Wuhan, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Song","sequence":"additional","affiliation":[{"name":"Institute of Lifeomics, Academy of Military Medical Sciences, National Engineering Research Center for Protein Drugs, Beijing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Tsinghua Clinical Research Institute, School of Medicine, Tsinghua University, Beijing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Ma","sequence":"additional","affiliation":[{"name":"Mabwell (Shanghai) Bioscience Co, Ltd, Shanghai, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhitian","family":"Hu","sequence":"additional","affiliation":[{"name":"Mabwell (Shanghai) Bioscience Co, Ltd, Shanghai, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Datao","family":"Liu","sequence":"additional","affiliation":[{"name":"Mabwell (Shanghai) Bioscience Co, Ltd, Shanghai, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinhan","family":"Guo","sequence":"additional","affiliation":[{"name":"Mabwell (Shanghai) Bioscience Co, Ltd, Shanghai, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhai","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Jiangsu, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Senior Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"coi230085r1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction.","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"coi230085r2","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1152\/physrev.00012.2019","article-title":"Bone metastasis: mechanisms, therapies, and biomarkers.","volume":"101","author":"Cl\u00e9zardin","year":"2021","journal-title":"Physiol Rev"},{"key":"coi230085r3","first-page":"7","article-title":"Expert consensus on the clinical diagnosis and treatment of bone metastasis of breast cancer and bone related diseases in (2014vision).","volume":"4","author":"Jiang","year":"2015","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"2","key":"coi230085r4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","article-title":"Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007).","volume":"129","author":"Yong","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"coi230085r5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies.","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"coi230085r6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"coi230085r7","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function.","volume":"26","author":"Jamal","year":"2011","journal-title":"J Bone Miner Res"},{"key":"coi230085r8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41232-019-0111-3","article-title":"RANKL biology: bone metabolism, the immune system, and beyond.","volume":"40","author":"Ono","year":"2020","journal-title":"Inflamm Regen"},{"issue":"6","key":"coi230085r9","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/ecc.2010.19.issue-6","article-title":"The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain.","volume":"19","author":"Pockett","year":"2010","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"1","key":"coi230085r10","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2016.1272308","article-title":"Key drivers for market penetration of biosimilars in Europe.","volume":"5","author":"R\u00e9muzat","year":"2017","journal-title":"J Mark Access Health Policy"},{"key":"coi230085r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108666","article-title":"The similarity of pharmacokinetics, pharmacodynamics, safety, and immunogenicity between recombinant fully human anti-RANKL monoclonal antibody injection (MW032) and denosumab (Xgeva) in healthy Chinese subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled clinical study.","volume":"107","author":"Hou","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"coi230085r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2020.100272","article-title":"What is the relationship between bone turnover markers and skeletal-related events in patients with bone metastases from solid tumors and in patients with multiple myeloma? A systematic review and meta-regression analysis.","volume":"12","author":"Jiang","year":"2020","journal-title":"Bone Rep"},{"issue":"12","key":"coi230085r15","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s12094-016-1590-1","article-title":"SEOM Clinical Guideline for bone metastases from solid tumours (2016).","volume":"18","author":"Gr\u00e1valos","year":"2016","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"coi230085r16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10549-005-9094-7","article-title":"Can bone markers guide more effective treatment of bone metastases from breast cancer?","volume":"97","author":"Clemons","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"28","key":"coi230085r17","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.","volume":"25","author":"Lipton","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi230085r18","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/cas.2008.99.issue-6","article-title":"Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases.","volume":"99","author":"Yonemori","year":"2008","journal-title":"Cancer Sci"},{"issue":"9","key":"coi230085r19","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi230085r20","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"16","key":"coi230085r21","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"issue":"35","key":"coi230085r22","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9768","key":"coi230085r23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"coi230085r24","doi-asserted-by":"publisher","first-page":"e1903","DOI":"10.1097\/MJT.0000000000000391","article-title":"Statistical primer on biosimilar clinical development.","volume":"23","author":"Isakov","year":"2016","journal-title":"Am J Ther"},{"issue":"1-2","key":"coi230085r26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1359-6446(05)03638-X","article-title":"Elimination mechanisms of therapeutic monoclonal antibodies.","volume":"11","author":"Tabrizi","year":"2006","journal-title":"Drug Discov Today"},{"key":"coi230085r12","unstructured":"Accessed March 23, 2023. https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=f044cdf4b7d7286aa12ffb85fc81a74c"},{"key":"coi230085r13","unstructured":"Accessed March 23, 2023. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/1b7602646b1f919e80c1cc2976f4af52"},{"key":"coi230085r25","unstructured":"Accessed August 3, 2023. https:\/\/www.fdanews.com\/ext\/resources\/files\/archives\/n\/NoninferiorityGuidance.pdf"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2814859\/jamaoncology_zhang_2024_oi_230085_1712704300.30566.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T15:03:04Z","timestamp":1713452584000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2814859"}},"subtitle":["A Randomized, Double-Blind, Phase 3 Equivalence Trial"],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.6520","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}